Damora Therapeutics, Inc. (DMRA)
$21.08+2.53%Close
SELLCRISIS · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.3B
- Beta
- 1.44
- P/E (TTM)
- -0.16
- Short % float
- 11.48%
- Days to cover
- 4.8
- SI change
- +0.0%
- 1W
- +2.08%
- 1M
- -21.46%
- vs SPY 1W
- +0.92%
- vs SPY 1M
- -24.45%
Industry peers
FMP comparable companies · ranked by market cap
- GMABBUYGenmab A/S$23.2BBULLQ 21$37.80+2.83%
- INCYSELLIncyte Corporation$22.9BBEARQ 13$112.73+0.04%
- IRONSELLDisc Medicine, Inc.$2.4BCRISISQ 1$61.65+2.12%
- QURESELLuniQure N.V.$1.6BCRISISQ 17$23.06+0.22%
- COAGSELLHemab Therapeutics Holdings, Inc. Common Stock$1.3BQ -3$28.37+2.36%
- RIGLBUYRigel Pharmaceuticals, Inc.$853MBULLQ 9$46.11+0.74%
- GERNSELLGeron Corporation$776MRECOVERYQ 11$1.21+0.82%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on DMRA?
- LOPJLB’s latest quantitative signal on Damora Therapeutics, Inc. (DMRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DMRA in?
- Damora Therapeutics, Inc. (DMRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Damora Therapeutics, Inc. (DMRA) do?
- Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The companyâs lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent …